05/25/23 4:01 PMNasdaq : GNLX clinical triallow floatGenelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) OncologyPhase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3RHEA-AIneutral
05/15/23 7:00 AMNasdaq : GNLX low floatGenelux Corporation Announces $33 Million Private PlacementGenelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximatelyRHEA-AIneutral
03/23/23 7:00 AMNasdaq : GNLX low floatGenelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressiveRHEA-AIneutral
01/25/23 9:00 PMNasdaq : GNLX IPOofferinglow floatGenelux Corporation Announces Pricing of Initial Public OfferingGenelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressiveRHEA-AIneutral
